202 related articles for article (PubMed ID: 25685858)
1. Siltuximab: a new option for the management of Castleman's disease.
Barquero N
Drugs Today (Barc); 2015 Jan; 51(1):21-8. PubMed ID: 25685858
[TBL] [Abstract][Full Text] [Related]
2. Siltuximab (CNTO 328): a promising option for human malignancies.
Chen R; Chen B
Drug Des Devel Ther; 2015; 9():3455-8. PubMed ID: 26170629
[TBL] [Abstract][Full Text] [Related]
3. Siltuximab for multicentric Castleman disease.
Liu YC; Stone K; van Rhee F
Expert Rev Hematol; 2014 Oct; 7(5):545-57. PubMed ID: 25110138
[TBL] [Abstract][Full Text] [Related]
4. Dose selection of siltuximab for multicentric Castleman's disease.
Mayer CL; Xie L; Bandekar R; Qi M; van de Velde H; Reddy M; Qin X; Davis HM; Puchalski TA
Cancer Chemother Pharmacol; 2015 May; 75(5):1037-45. PubMed ID: 25784388
[TBL] [Abstract][Full Text] [Related]
5. Castleman's disease and sarcoidosis, a rare association resulting in a "mixed" response: a case report.
Mohammed A; Janku F; Qi M; Kurzrock R
J Med Case Rep; 2015 Feb; 9():45. PubMed ID: 25884809
[TBL] [Abstract][Full Text] [Related]
6. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.
van Rhee F; Wong RS; Munshi N; Rossi JF; Ke XY; Fosså A; Simpson D; Capra M; Liu T; Hsieh RK; Goh YT; Zhu J; Cho SG; Ren H; Cavet J; Bandekar R; Rothman M; Puchalski TA; Reddy M; van de Velde H; Vermeulen J; Casper C
Lancet Oncol; 2014 Aug; 15(9):966-74. PubMed ID: 25042199
[TBL] [Abstract][Full Text] [Related]
7. Siltuximab (Sylvant) for treatment of multicentric castleman's disease.
Med Lett Drugs Ther; 2015 Jan; 57(1459):e8. PubMed ID: 25555075
[No Abstract] [Full Text] [Related]
8. Siltuximab: A Review in Idiopathic (Human Herpesvirus-8-Negative) Multicentric Castleman Disease.
Lyseng-Williamson KA
BioDrugs; 2015 Dec; 29(6):399-406. PubMed ID: 26394632
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapeutic implication of IL-6 blockade.
Tanaka T; Kishimoto T
Immunotherapy; 2012 Jan; 4(1):87-105. PubMed ID: 22150003
[TBL] [Abstract][Full Text] [Related]
10. Expression of a virus-derived cytokine, KSHV vIL-6, in HIV-seronegative Castleman's disease.
Parravicini C; Corbellino M; Paulli M; Magrini U; Lazzarino M; Moore PS; Chang Y
Am J Pathol; 1997 Dec; 151(6):1517-22. PubMed ID: 9403701
[TBL] [Abstract][Full Text] [Related]
11. Impact of siltuximab on patient-related outcomes in multicentric Castleman's disease.
Sitenga J; Aird G; Ahmed A; Silberstein PT
Patient Relat Outcome Meas; 2018; 9():35-41. PubMed ID: 29391839
[TBL] [Abstract][Full Text] [Related]
12. Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease.
Fajgenbaum DC; Kurzrock R
Immunotherapy; 2016; 8(1):17-26. PubMed ID: 26634298
[TBL] [Abstract][Full Text] [Related]
13. Clinical development of siltuximab.
Davis CC; Shah KS; Lechowicz MJ
Curr Oncol Rep; 2015 Jul; 17(7):29. PubMed ID: 25986720
[TBL] [Abstract][Full Text] [Related]
14. Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma.
Ferrario A; Merli M; Basilico C; Maffioli M; Passamonti F
Expert Opin Investig Drugs; 2017 Mar; 26(3):367-373. PubMed ID: 28140696
[TBL] [Abstract][Full Text] [Related]
15. [Advances in etiology and management of Castleman's disease].
Han X; Zhou DB
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct; 31(5):639-43. PubMed ID: 19968087
[TBL] [Abstract][Full Text] [Related]
16. The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castleman's disease.
Sun Y; Wang D; Salvadore G; Hsu B; Curran M; Casper C; Vermeulen J; Kent JM; Singh J; Drevets WC; Wittenberg GM; Chen G
Brain Behav Immun; 2017 Nov; 66():156-164. PubMed ID: 28676350
[TBL] [Abstract][Full Text] [Related]
17. Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders.
Paul-Pletzer K
Drugs Today (Barc); 2006 Sep; 42(9):559-76. PubMed ID: 17028666
[TBL] [Abstract][Full Text] [Related]
18. Therapy of Castleman's disease with siltuximab - case report and review of literature.
Adam Z; Zeman D; Chodacki A; Pour L; Horváth T; Benda P; Adamová Z; Krejčí M; Tomíška M; Boichuk I; Král Z
Klin Onkol; 2023; 37(4):320-329. PubMed ID: 38195387
[TBL] [Abstract][Full Text] [Related]
19. Review of siltuximab in the treatment of multicentric Castleman's disease.
Sarosiek S; Shah R; Munshi NC
Ther Adv Hematol; 2016 Dec; 7(6):360-366. PubMed ID: 27904739
[TBL] [Abstract][Full Text] [Related]
20. Clinical studies in patients with Castleman's disease, Crohn's disease, and rheumatoid arthritis in Japan.
Nishimoto N
Clin Rev Allergy Immunol; 2005 Jun; 28(3):221-30. PubMed ID: 16129906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
